UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center

Clinical breast cancer, 2023-01, Vol.23 (1), p.38-44

2023

Volltextzugriff (PDF)

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Breast cancer research and treatment, 2024-10, Vol.207 (3), p.599-609

2024

Volltextzugriff (PDF)

Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Breast cancer research and treatment, 2024-10, Vol.207 (3), p.611-614

2024

Volltextzugriff (PDF)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget, 2018-04, Vol.9 (31), p.22137-22146

2018

Volltextzugriff (PDF)

Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx

Annals of surgical oncology, 2019-10, Vol.26 (10), p.3152-3158

2019

Volltextzugriff (PDF)

Spatially variant immune infiltration scoring in human cancer tissues

NPJ precision oncology, 2022-09, Vol.6 (1), p.60-60, Article 60

2022

Volltextzugriff (PDF)

Extended Endocrine Therapy: Is 5 Years Enough?

Current Oncology Reports, 2017-03, Vol.19 (3), p.16-16, Article 16

2017

Volltextzugriff (PDF)

Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer

Clinical breast cancer, 2018-04, Vol.18 (2), p.168-174.e2

2018

Volltextzugriff (PDF)

Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy

Clinical breast cancer, 2023-12, Vol.23 (8), p.832-834

2023

Volltextzugriff (PDF)

Novel Therapeutics in Advanced Breast Cancer: A Review of Current Phase I Clinical Trials

Current breast cancer reports, 2025-12, Vol.17 (1), Article 2

2025

Volltextzugriff (PDF)

Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1074-1074

2022

Volltextzugriff (PDF)

Acquired hemophilia A: Diagnosis, aetiology, clinical spectrum and treatment options

Autoimmunity reviews, 2011-04, Vol.10 (6), p.311-316

2011

Volltextzugriff (PDF)

Patient understanding of immunotherapy and its side effects for women with triple negative breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24046-e24046

2023

Volltextzugriff (PDF)

Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events

Hepatology (Baltimore, Md.), 2012-11, Vol.56 (5), p.1741-1750

2012

Volltextzugriff (PDF)

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

Breast cancer research and treatment, 2024-11, Vol.208 (1), p.203-214

2024

Volltextzugriff (PDF)

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3176-TPS3176

2022

Volltextzugriff (PDF)

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients

Cancer treatment reviews, 2018-02, Vol.63, p.116-121

2018

Volltextzugriff (PDF)

Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-01-02-OT2-01-02

2022

Volltextzugriff (PDF)

Treatment of Pregnancy-Associated Breast Cancer

Current breast cancer reports, 2021-06, Vol.13 (2), p.81-86

2021

Volltextzugriff (PDF)

Outcomes for black versus white women with stage IV breast cancer enrolled on investigator-initiated clinical trials at Emory

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1086-1086

2020

Volltextzugriff (PDF)

Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.603-603

2024

Volltextzugriff (PDF)

Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23096-e23096

2019

Volltextzugriff (PDF)

Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1134-TPS1134

2023

Volltextzugriff (PDF)

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

The Journal of clinical investigation, 2024-05, Vol.134 (10)

2024

Volltextzugriff (PDF)

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

The Journal of clinical investigation, 2024-05, Vol.134 (10), p.1-19

2024

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx

Spatially variant immune infiltration scoring in human cancer tissues

Extended Endocrine Therapy: Is 5 Years Enough?

Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer

Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy

Novel Therapeutics in Advanced Breast Cancer: A Review of Current Phase I Clinical Trials

Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center

Acquired hemophilia A: Diagnosis, aetiology, clinical spectrum and treatment options

Patient understanding of immunotherapy and its side effects for women with triple negative breast cancer

Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients

Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Treatment of Pregnancy-Associated Breast Cancer

Outcomes for black versus white women with stage IV breast cancer enrolled on investigator-initiated clinical trials at Emory

Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study

Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers

Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC)

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

Suchergebnisse filtern